Clario, a prominent healthcare research and technology company specializing in clinical trial solutions, has announced its acquisition of ArtiQ, a technology firm known for its expertise in artificial intelligence (AI). This strategic move bolsters Clario's Respiratory Solutions portfolio, empowering the company to further harness AI's potential across its service lines. With a focus on improving the quality and efficiency of clinical trial execution, Clario aims to leverage ArtiQ's technology to scale AI for overreading, ensuring data quality and streamlining processes for patients globally.
Marko Topalovic, the former leader of ArtiQ, will now spearhead Clario's overall AI strategy, marking a significant milestone for both companies. The integration of ArtiQ's technology into Clario's portfolio not only enhances spirometry data analysis but also promises to minimize patient burden and improve trial outcomes. This acquisition, coupled with Clario's previous acquisition of Inofab Health, underscores the company's commitment to advancing AI within clinical trials and expanding its presence in the broader healthcare market. With a track record of delivering high-quality data in clinical trials, Clario remains dedicated to its mission of transforming patient lives worldwide through innovative healthcare solutions.
